Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab and Tislelizumab + Chemotherapy in Neo-adjuvant Pancreatic Cancer
NCT05984602Phase 1Active, not recruiting
- Sponsor
- NYU Langone Health
- Start
- Jul 2023
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of canakinumab and tislelizumab in pancreatic cancer (PC), sponsored by NYU Langone Health. Primary endpoints: Number of dose limiting toxicities at 56 days and Number of patients who proceeded to surgical resection up to 6 months. Started Jul 2023; status: active, not recruiting.
02
Drugs
canakinumabtislelizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05984602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984602.